Unknown OBSERVATIONAL NCT05923879

Mechanism Investigation of Selinexor Combined With Lenalidomide and Rituximab in the Treatment of Diffuse Large B-cell Lymphoma

Sponsor: Ruijin Hospital

Conditions Lymphoma, Large B-Cell, Diffuse

Interventions Selinexor combined with lenalidomide and rituximab

Updated 4 times since 2023 Last updated: Jun 20, 2023 Started: Jun 30, 2023 Primary completion: Jun 30, 2025 Completion: Jun 30, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Lymphoma, Large B-Cell, Diffuse, this trial is ongoing. The trial is conducted by Ruijin Hospital and has accumulated 4 data snapshots since 2023. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

4 versions recorded

Aug 2025 — Present [monthly]

Unknown

Status: Not Yet Recruiting → Unknown
Sep 2024 — Aug 2025 [monthly]

Not Yet Recruiting
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting
Jul 2023 — Jul 2024 [monthly]

Not Yet Recruiting

First recorded

Jun 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ruijin Hospital

Data source: Ruijin Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China